FL firm wins patent for synthetic cannabis-based therapy

A Florida biopharmaceutical company said it has been awarded the first U.S. patent for the commercial development of synthetic cannabis-based medical treatments.

Tampa-based Teewinot Life Sciences, formerly known as CBC Biotechnologies, said in a news release the patent – U.S. Patent No. 9,359,625 – claims a biosynthetic process for manufacturing the cannabinoids THCA, CBDA and CBCA.

The company said its synthetic production method is faster than plant cultivation, does less environmental damage and results in a purer cannabinoids.

“Our use of synthetic biology represents a significant advancement from current plant extraction and chemical synthesis methods,”¬†Jeff Korentur, Teewinot’s CEO, said in the news release.

“We are seeking partners interested in using the cannabinoids, cannabinoid pro-drugs, and cannabinoid analogs we manufacture in research and clinical trials to fill critical gaps in current and future pharmaceutical offerings.”

The patent is owned by Teewinot’s wholly owned Irish subsidiary, Full Spectrum Laboratories Ltd.

Teewinot received a $7.4 million venture capital infusion in March, according to the Tampa Bay Business Journal.

7 comments on “FL firm wins patent for synthetic cannabis-based therapy
  1. Sterling McVay on

    Synthetic ‘will NEVER BE’ the Same as ‘Nature’. Nature ‘Imparts’ PRANA, or ‘Life Energy’ via the ‘Sun’, and all the ‘other’ ‘Elements’, include, ‘specifically’, the ‘Ether’, that TESLA, ‘spoke of’. This is ‘Sad’ for Florida, yet it ‘reveals’, that Florida is ‘Right-Wing’, Neo-Con, ‘controlled’ State, that ‘Favors’ BIG BUSINESS, Over the People.

    Reply
  2. ROBERT E HUNT on

    All of us at Tuatara Capital are very proud of the accomplishments that Teewinot Life Sciences have realized since we led their Series A funding last December. Teewinot will continue to push the envelope in bio-synthetic cannabinoid development and formulation. It is mission critical to the entire cannabis industry to have a pharmaceutical company lead the way toward widespread acceptance of cannabinoids as medicine.

    Reply
  3. Nola Wyse on

    A pharmaceutical company to help pave the way is not all bad. However we keep repeating our mistakes over and over again with Synthetics. Natural is the only way we will be able to heal ourselves and the beautiful planet we live on.

    Reply
  4. Robert Hunt on

    Nola, Sterling and Seth

    We don’t disagree, which is why Teewinot is utilizing a Bio-synthetic process. I don’t know if you are all familiar with the term, but what Teewinot is doing is replicating what the plant does naturally to produce cannabinoids but without having to grow the plant. What this means is they do not have to grow a harvest, dry, cure, extract, extract again to remove lipids and waxes and other materials and then try and extract each cannabinoid individually. Doing all of that often requires the use of solvents, ethanol, and other potentially harmful materials. It also extracts any harmful pesticides, herbicides, molds, mildews, heavy metals, residual solvents, etc. that may have been used in the cultivation process. Bio-synthetic production allows for production of natural (biology based, not chemistry based) cannabinoids that can then be used to formulate any ratios of that can be imagined to treat specific ailments in ways that the plant by itself never could. If you really believe in the efficacious nature of the cannabis plant, and we do, then you also must believe that it will be combinations of cannabinoids, flavinoids and terpenes that will ultimately be the key that unlocks the way to treat many illnesses. That is what Teewinot does and you should be celebrating this. It will move the needle for everyone on a Federal basis in the way that growing, harvesting and selling “medicine” across the counter with a “budtender” never will.

    Reply
    • Dave P. on

      “Moving the needle on a Federal basis” is not what is needed, as each state is doing very well independently, thank you. Federal prohibition is the only thing keeping the major corporations out of Cannabis, and should be maintained. Production of individual cannabinoids by a genetically modified yeast is not my idea of progress (transgenic technology not nearly being “natural”) and will not in any way substitute for the whole plant and its complex contents. Most people in this business will certainly not be “celebrating” this development, but are hoping that the economic realities of a high-tech approach will spell the business demise of all involved.

      Reply
  5. James Papsdorf on

    How does this process differ from that of Zynerba which also claims patent coverage for a synthetic cannabis compound which will be delivered transdermally.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *